Skip to content

Study of Lactulose in Children With Chronic Liver Disease

Improvement of Cognitive Function and Healthcare -Related Quality of Life After Lactulose Treatment in Children With Chronic Liver Disease

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00811434
Acronym
MHE
Enrollment
16
Registered
2008-12-19
Start date
2009-01-31
Completion date
2010-11-30
Last updated
2014-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal Hepatic Encephalopathy

Keywords

encephalopathy, pediatric liver disease, pediatric cirrhosis, serum ammonia levels

Brief summary

Pediatric patients with chronic liver disease may have Minimal Hepatic Encephalopathy(MHE)which can cause changes in behavior,intelligence and neurological function.By utilizing cognitive and developmental testing we will determine if patients have MHE. If so, we will trial 3 months of blinded placebo or Lactulose treatment followed by a washout period with no treatment. At this time patients are re-tested and then begin another three month period switching to the opposite treatment of first 3 months.Final cognitive/developmental testing will determine if Lactulose treatment has any effect on MHE.

Detailed description

In addition ,serum ammonia levels will be obtained at beginning of study,post-washout and at end of study to evaluate Lactulose effect on serum ammonia.

Interventions

DRUGLactulose

1.5cc/kg/day po for three months

DRUGplacebo

1.5 ml sugar water/kg day for three months

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of MHE as result of cognitive, developmental testing, pediatric pt. with cirrhosis as evidenced by imaging/biopsy

Exclusion criteria

* patients with neurological,psychiatric or unstable medical conditions which may contribute to impaired cognitive function. * patients with known hearing or vision difficulties. * those patients who do not speak English will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Minimal Hepatic Encephalopathy (MHE) in Children With Cirrhosisbaselinefailure of one cognitive function test indicates presence of MHE

Secondary

MeasureTime frameDescription
Health Related Quality of Life (HRQOL)baselineHRQOL administered to parents prior to treatment
Effeccts of Lactulose Treatment on MHE as Measaured by Cognitive Functionbefore and after each treatment periodMHE as measured by failure of one or more cognitive test

Countries

United States

Participant flow

Recruitment details

Informed consent was obtained on the first subject 1/16/2009 and recruitment continued until study closure in November 2010.

Pre-assignment details

Two subjects were withdrawn prior to randomization.Two did not meet entry criteria.

Participants by arm

ArmCount
All Participants
all aprticipants who were randomized to receive treatment
12
Total12

Baseline characteristics

CharacteristicAll Participants
Age, Categorical
<=18 years
12 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 120 / 9
serious
Total, serious adverse events
0 / 120 / 9

Outcome results

Primary

Incidence of Minimal Hepatic Encephalopathy (MHE) in Children With Cirrhosis

failure of one cognitive function test indicates presence of MHE

Time frame: baseline

ArmMeasureValue (NUMBER)
All Randomized ParticipantsIncidence of Minimal Hepatic Encephalopathy (MHE) in Children With Cirrhosis6 participant
Secondary

Effeccts of Lactulose Treatment on MHE as Measaured by Cognitive Function

MHE as measured by failure of one or more cognitive test

Time frame: before and after each treatment period

Population: data not collected as planned

Secondary

Health Related Quality of Life (HRQOL)

HRQOL administered to parents prior to treatment

Time frame: baseline

Population: data not collected as planned

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026